Clinical Trials Browser

Phase 3 × Uterine Cervical Dysplasia × 1 year × Clear all

NCT04537156 2025-11-21

Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Phase 3 Active not recruiting

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Condylomata Acuminata